{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000025","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.303259+00:00","generated_at":"2026-05-23T00:11:33.024512+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere Q1 net product sales $75.9M; FILSPARI sales $55.9M, net loss narrows to $0.47/share","bullets":["Net product sales $75.9M (1Q25) vs $40.0M (1Q24), driven by FILSPARI launch.","FILSPARI U.S. net sales $55.9M; 703 new patient start forms in quarter.","Net loss $41.2M ($0.47/share) vs $136.1M ($1.76/share) YoY; adj. net loss $16.9M.","Cash & securities $322.2M; sNDA submitted for full approval of FILSPARI in FSGS.","EU and UK converted FILSPARI to full approval in IgAN; $17.5M milestone from CSL Vifor expected Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000025","json":"https://secwatch.observer/filing/0001438533-25-000025.json","markdown":"https://secwatch.observer/filing/0001438533-25-000025.md","text":"https://secwatch.observer/filing/0001438533-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000025/0001438533-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000025/tvtx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:11:33.024512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}